文献速递青光眼神经眼科

晚期青光眼患者中心视觉功能受威胁的因素:一项前瞻性纵向观察研究

Factors Threatening Central Visual Function of Patients with Advanced Glaucoma: A Prospective Longitudinal Observational Study.
PubMed 文献 · Ophthalmology · 2021-12-08

该前瞻性观察5年研究纳入175例眼压控制良好的晚期青光眼患者(175眼),每6个月行HFA 10-2和BCVA检查、每12个月行HFA 24-2检查,用Cox模型分析中心视觉功能恶化的危险因素。5年时HFA 10-2、24-2和BCVA恶化概率分别为0.269±0.043、0.173±0.031和0.194±0.033。基线BCVA较低、HFA 24-2 MD较好、使用全身降压药、β-视乳头旁萎缩面积与视盘面积比值较大是显著预后因素。

要点

  • 晚期青光眼眼压控制良好者5年HFA 10-2恶化概率为0.269±0.043。
  • 基线BCVA较低与HFA 10-2进一步恶化显著相关(P=0.012)。
  • 使用全身降压药与HFA 24-2和BCVA恶化均显著相关(P=0.009和P=0.025)。

核心结论

  • 在眼压控制良好的晚期青光眼中,BCVA、β-视乳头旁萎缩面积与视盘面积比值及使用全身降压药是中心视觉功能进一步恶化的显著预后因素。

研究设计与样本

  • 前瞻性、观察性5年研究,纳入175例晚期青光眼患者的175眼,眼压控制良好,HFA 24-2 MD≤-20 dB且BCVA为20/40。

主要发现

  • 5年时HFA 10-2、HFA 24-2和BCVA恶化概率分别为0.269±0.043、0.173±0.031和0.194±0.033。
  • 基线BCVA较低与HFA 10-2结果进一步恶化显著相关(P=0.012)。
  • HFA 24-2 MD较好(P<0.001)和使用全身降压药(P=0.009)与HFA 24-2结果进一步恶化显著相关。
  • β-视乳头旁萎缩面积与视盘面积比值较大(P<0.001)、使用全身降压药(P=0.025)和BCVA较低(P=0.042)分别与BCVA进一步恶化显著相关。

关键数值与推荐

  • HFA 10-2恶化定义为≥3次连续检查中同一≥3个点总偏差斜率≤-1 dB/年且P<0.01。
  • HFA 24-2恶化定义为≥2次连续检查中晚期青光眼干预研究评分增加≥2。
  • BCVA恶化定义为≥2次连续检查中最小分辨角对数(logMAR)增加≥0.2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify risk factors for further deterioration of central visual function in advanced glaucoma eyes. DESIGN: Prospective, observational 5-year study. PARTICIPANTS: Advanced glaucoma patients with well-controlled intraocular pressure (IOP), mean deviation (MD) of the Humphrey Field Analyzer (HFA) 24-2 program ≤-20 dB and best-corrected visual acuity (BCVA) of 20/40. METHODS: The HFA 10-2 test and BCVA examination were performed every 6 months, and the HFA 24-2 test was performed every 12 months for 5 years. The Cox proportional hazards model was used to identify risk factors for deterioration of HFA 10-2 and 24-2 results and BCVA. MAIN OUTCOME MEASURES: Deterioration of HFA 10-2 results was defined by the presence of the same ≥3 points with negative total deviation slope ≤-1 dB/year at P < 0.01 on ≥3 consecutive tests, deterioration of HFA 24-2 results by an increase ≥2 in the Advanced Glaucoma Intervention Study score on ≥2 consecutive tests, and deterioration of BCVA by an increase of ≥0.2 logarithm of the minimum angle of resolution (logMAR) on ≥2 consecutive tests. RESULTS: A total of 175 eyes of 175 patients (mean age, 64.1 years; mean baseline IOP, 13.2 mmHg; mean BCVA, 0.02 logMAR; mean HFA 24-2 and 10-2 MD, -25.9 and -22.9 dB, respectively) were included. The probabilities of deterioration in HFA 10-2 and 24-2 results and BCVA were 0.269 ± 0.043 (standard error), 0.173 ± 0.031, and 0.194 ± 0.033, respectively, at 5 years. Lower BCVA at baseline (P = 0.012) was associated significantly with further deterioration of HFA 10-2 results. Better HFA 24-2 MD (P < 0.001) and use of systemic antihypertensive agents (P = 0.009) were associated significantly with further deterioration of HFA 24-2 results, and a greater β-peripapillary atrophy area-to-disc area ratio (P < 0.001), use of systemic antihypertensive agents (P = 0.025), and lower BCVA (P = 0.042) were associated significantly with further deterioration of BCVA, respectively. CONCLUSIONS: In advanced glaucoma eyes with well-controlled IOP, BCVA, β-peripapillary atrophy area-to-disc area ratio, and use of systemic antihypertensive agents were significant prognostic factors for further deterioration of central visual function.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Sugisaki K, Inoue T, Yoshikawa K, et al. Factors Threatening Central Visual Function of Patients with Advanced Glaucoma: A Prospective Longitudinal Observational Study. Ophthalmology. 2021. PMID: 34890684. doi:10.1016/j.ophtha.2021.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。